Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(04): 290-295
DOI: 10.1055/s-0042-1750404
Original Article

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma

Enrique Cadena-Piñeros 
1   Department of Head and Neck, National Cancer Institute, Bogotá, D.C., Colombia
2   Department of Otorhinolaryngology, National University of Colombia and National University Hospital of Colombia, Bogotá, D.C., Colombia
3   Department of Otorhinolaryngology and Head and Neck, Marly Clinic, Bogotá, D.C., Colombia
,
Judith Vásconez Escobar 
1   Department of Head and Neck, National Cancer Institute, Bogotá, D.C., Colombia
4   Department of Medicine, Universidad Militar Nueva Granada, Bogotá, D.C, Colombia
,
Jose A. Carreño 
5   Department of Cancer Clinical Research, National Cancer Institute, Bogotá, D.C., Colombia
,
Julian G. Rojas 
6   Department of Nuclear Medicine, National Cancer Institute, Bogotá, D.C., Colombia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Differentiated thyroid carcinoma (DTC) has increased incidence. Intermediate- and high-risk patients have lymph node relapse rate ranging from 10 to 50%, and receive multiple reinterventions, increasing the morbidity of the disease. Currently, there are no established guidelines for the use of second radioactive iodine (RAI) therapy after the reintervention for local recurrence.

Materials and Methods This is a retrospective review of the medical records of 1,299 patients treated from January 2016 to July 2019 with DTC. We included 48 patients who received total thyroidectomy, RAI remnant ablation, surgery to remove the locally recurrent/persistent papillary thyroid carcinoma (PTC), and received a second RAI therapy.

Results There were no significant differences between thyroglobulin (Tg) levels before reoperation (Tg0), Tg levels postoperatively (Tg1), and Tg levels after 6 months of second adjuvant RAI therapy (Tg2). However, we evidenced a 69.79% drop in first Tg levels (Tg0: 24.7 vs. Tg1: 7.56, p=0.851) and 44.4% decrease in second Tg levels (Tg1: 7.56 vs. Tg2: 4.20, p=0.544). Also, 77.1% of the patients did not have another documented recurrence. The median relapse-free time was 10.9 months (range: 1.3–58.2 months).

Conclusion The results of the study cannot assess that a second RAI treatment after reoperation for locoregionally persistent or recurrent disease have a significant impact on treatment outcomes in intermediate- or high-risk patients with PTC. However, the 77.1% of patients have not presented a second documented recurrence and the median values of Tg and TgAb levels showed a substantial decrease after surgery and second RAI treatment.

Keywords

thyroid cancer - local neoplasm recurrence - thyroglobulin - nuclear medicine - iodine - reoperation

The work was conducted at the National Cancer Institute, Bogotá, Colombia.




Publication History

Article published online:
02 September 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214
    CrossrefPubMedGoogle Scholar
  • 3 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
    CrossrefPubMedGoogle Scholar
  • 4 Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130 (S2): S150-S160
    CrossrefPubMedGoogle Scholar
  • 5 Tuttle RM, Tala H, Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20 (12) 1341-1349
    CrossrefPubMedGoogle Scholar
  • 6 Tuttle MR, Morris LF, Haugen BR. et al. Thyroid - differentiated and anaplastic carcinoma. In: Amin MB, Edge SB, Greene FL. eds. AJCC Cancer Staging Manual. 8th ed. Chicago, IL: Springer; 2017: 881-898
    Google Scholar
  • 7 Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43 (02) 401-421
    CrossrefPubMedGoogle Scholar
  • 8 Hirsch D, Gorshtein A, Robenshtok E. et al. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J Clin Endocrinol Metab 2018; 103 (02) 469-476
    CrossrefPubMedGoogle Scholar
  • 9 Yim JH, Kim WB, Kim EY. et al. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation. J Clin Endocrinol Metab 2011; 96 (12) 3695-3700
    CrossrefPubMedGoogle Scholar
  • 10 Tuncel M, Süslü N. Radioguided occult lesion localization in patients with recurrent thyroid cancer. Eur Arch Otorhinolaryngol 2019; 276 (06) 1757-1766
    CrossrefPubMedGoogle Scholar
  • 11 Cadena-Piñeros E, Parra-Charris JS. Radioguided Surgery of non-palpable neck lymph node in lymphoma patients. Indian J Otolaryngol Head Neck Surg 2019; 71 (04) 430-434
    CrossrefPubMedGoogle Scholar
  • 12 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97 (05) 418-428
    CrossrefPubMedGoogle Scholar
  • 13 Piccardo A, Puntoni M, Bottoni G. et al. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. Eur J Nucl Med Mol Imaging 2017; 44 (06) 926-934
    CrossrefPubMedGoogle Scholar
  • 14 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154 (06) 787-803
    CrossrefPubMedGoogle Scholar
  • 15 Bouvet C, Barres B, Kwiatkowski F. et al. Re-treatment with adjuvant radioactive iodine does not improve recurrence-free survival of patients with differentiated thyroid cancer. Front Endocrinol (Lausanne) 2019; 10: 671
    CrossrefPubMedGoogle Scholar
  • 16 Gulec SA, Ahuja S, Avram AM. et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid 2021; 31 (07) 1009-1019
    CrossrefPubMedGoogle Scholar
  • 17 Schuff KG, Weber SM, Givi B, Samuels MH, Andersen PE, Cohen JI. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. Laryngoscope 2008; 118 (05) 768-775
    CrossrefPubMedGoogle Scholar
  • 18 Hung ML, Wu JX, Li N, Livhits MJ, Yeh MW. Association of Radioactive Iodine Administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer. JAMA Surg 2018; 153 (12) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 19 Heaton CM, Chang JL, Orloff LA. Prognostic implications of lymph node yield in central and lateral neck dissections for well-differentiated papillary thyroid carcinoma. Thyroid 2016; 26 (03) 434-440
    CrossrefPubMedGoogle Scholar